To test whether SNR-derived organoids can be used to model genetic neurodevelopmental disorders, we generated CRISPR/Cas9-engineered PSC lines with partial homozygous or complete hemizygous SHANK3 deletions (Fig. 10a, b). This evidence concerns the gene SHANK3 and neurodevelopmental disorder.